Navigation Links
MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients

WAYNE, N.J., May 3 /PRNewswire/ -- MAQUET Cardiovascular LLC today announced the launch in the United States of the new VASOSHIELD Pressure Controlling Syringe for use during Coronary Artery Bypass Graft (CABG) surgery.  The VASOSHIELD syringe limits internal "flushing" pressure and controls vessel distension when harvested grafts are irrigated in preparation for use in bypass surgery. Avoiding excessive pressure and limiting distension help maintain internal vessel integrity, which has been shown in clinical studies to be an important factor affecting conduit quality and long-term graft success. The new VASOSHIELD syringe will be demonstrated to cardiothoracic surgeons at the American Association of Thoracic Surgeons (AATS) 90th Annual Meeting, which is taking place from May 1-5, 2010 in Toronto, Canada.

"Accurately assessing and controlling pressure in grafts with a standard syringe can be difficult," said Michael J. Mack, M.D., Research Director, THE HEART HOSPITAL Baylor Plano. "We look forward to using the VASOSHIELD syringe because we expect it to assist us in the meticulous handling and preservation of vein grafts, which is vitally important to graft patency and positive patient outcomes. In addition, we look forward to gathering the data to help show the clinical benefit this new tool will provide. We believe it will complement the data we will obtain from the OPTION trial."

Dr. Mack is an investigator for the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in CABG surgery compared with historical data for open vein harvesting.  

When a vessel is prepared for use as a bypass graft it is frequently distended with a standard syringe to flush and check for leaks. If flushing pressure inside the vessel is not controlled, it has been observed to reach as high as 600 mm Hg, inadvertently damaging the internal vessel surface. By limiting the maximum pressure that can be applied during graft distension, this type of injury may be prevented, thereby improving the overall quality and patency of the graft long term.  

The VASOSHIELD Syringe allows the user to select one of three settings -- 150, 250 or 350 mm Hg – so that flushing pressure is adjusted in pre-set increments and uninterrupted flow is delivered during vein preparation.  It has been clinically shown that vessels flushed at controlled, lower pressures more effectively overcome spasm, maintain their endothelial and medial layers, and are more likely to provide a high-quality conduit for bypass surgery.

The VASOSHIELD Pressure Controlling Syringe is part of the VASOVIEW family of products from MAQUET Cardiovascular, which include a range of EVH technology options to perform minimally invasive vessel harvesting procedures.  

"As a leader in the field, MAQUET continues to advance cardiac bypass surgery techniques by investing in technologies that help improve patient outcomes and enhance quality of life," said Patrick Walsh, President of the Cardiac Surgery Business Unit at MAQUET Cardiovascular.  "The new VASOSHIELD syringe is yet another example of our commitment to supporting physicians with tools that optimize graft quality and improve standards of care."

About Vessel Harvesting

Vessels for bypass surgery may be retrieved using open surgery or through minimally-invasive endoscopic vessel harvesting (EVH). During EVH, a healthy blood vessel, such as the saphenous vein from the leg or the radial artery from the arm, is removed through a small incision for use during CABG surgery to bypass a blockage in the heart. Open vein harvesting requires a lengthy incision that is often extremely painful and prone to healing complications. EVH is considered a standard of care in the United States, with 80 percent of all CABG surgeries utilizing this technique.

About MAQUET Cardiovascular

MAQUET Cardiovascular was formed in 2003 and is a leader in providing innovative products for cardiac surgery, vascular intervention and cardiac support to hospitals and clinics and the cardiac surgeons, interventional cardiologists, perfusionists and other healthcare professionals who care for patients with cardiovascular disease. MAQUET Cardiovascular is focused on providing clinicians with future-oriented technology that fits into their daily practice and improves the therapeutic management of patients. MAQUET Cardiovascular continues to invest in the development of innovative technologies and solutions that advance clinical practice, improve patient outcomes and enhance quality of life.

MAQUET Cardiovascular provides healthcare professionals with products in four business units: Cardiopulmonary (perfusion products), Cardiac Surgery (clampless beating heart and endoscopic vessel harvesting), Vascular Interventions (grafts for vascular surgery), and Cardiac Assist (intra-aortic balloon counterpulsation therapy).

About The MAQUET Group

The MAQUET Group is the global market leader for Medical Systems, focusing on the Operating Room (OR), Cath Lab, Intensive Care Unit (ICU) and Patient Transport. The integrated products of MAQUET are specially designed to deliver optimal clinical treatment and therapeutic applications within acute care hospitals. MAQUET provides innovative medical solutions from three Divisions:

  • Cardiovascular with products for cardiac assist (intra-aortic balloon counterpulsation therapy), coronary artery bypass surgery, complex aortic surgery reconstruction, peripheral interventions and extracorporeal circulation.
  • Critical Care for intensive care ventilators and anesthesia machines
  • Surgical Workplaces for OR tables, lights and ceiling service units, flexible room design for OR, Cath Lab and ICU as well as digital OR integration.

MAQUET is a subsidiary of the publicly-listed Swedish GETINGE GROUP, a company with around $3 billion in revenues (2009 fiscal year) and 12,100 employees worldwide. In 2009 MAQUET itself generated revenues of around $1.5 billion. The company now has more than 5,000 employees in 36 international sales and service organizations, as well as a network of more than 250 sales representatives. Twelve manufacturing sites are located in 6 countries.

MAQUET – The Gold Standard.

SOURCE MAQUET Cardiovascular LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
2. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
3. LightLab Highlights OCT Market Leadership at the Society for Cardiovascular Angiography and Interventions
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
6. Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets
7. Reportlinker Adds Cardiovascular Catheters and Systems - Global Market Opportunities
8. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
9. ATS Medical to Participate in the 2009 Canaccord Adams Cardiovascular Conference
10. Cardiac Science to Present at Third Annual Canaccord Adams Cardiovascular Conference
11. Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):